Reducing men’s health drug costs: exploring the impact of the Mark Cuban Cost Plus Drug Company model on Medicare savings
In 2022, national health expenditures in the United States were estimated to have grown from 2.7% to 4.3% and increased further in 2023, reaching an estimated $5.2 trillion. Medicare alone, in 2021, accounted for 21% of national health care spending, amounting to $689 billion in total Medicare ex...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MRE Press
2024-12-01
|
| Series: | Journal of Men's Health |
| Subjects: | |
| Online Access: | https://oss.jomh.org/files/article/20241230-446/pdf/JOMH2024092701.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841561004010373120 |
|---|---|
| author | Adam Khan Karim Kari Eli Oldham Jacob Duncan Matthew Rashid Matt Vassar |
| author_facet | Adam Khan Karim Kari Eli Oldham Jacob Duncan Matthew Rashid Matt Vassar |
| author_sort | Adam Khan |
| collection | DOAJ |
| description | In 2022, national health expenditures in the United States were estimated to
have grown from 2.7% to 4.3% and increased further in 2023, reaching an
estimated $5.2 trillion. Medicare alone, in 2021, accounted for 21% of national
health care spending, amounting to $689 billion in total Medicare expenditures.
The Mark Cuban Cost Plus Drug Company (MCCPDC) Model offers a solution by
providing prescription medications at lower costs. The objective of this study
was to assess the effectiveness of the MCCPDC model in reducing men’s health drug
costs compared to Medicare Part D. A comprehensive analysis was conducted on the
“Men’s Health” drugs available through the MCCPDC. Prices, including dispensing
and shipping fees, were collected for the minimum quantity (30 count) and maximum
quantity (90 count) from the MCCPDC. Unit costs and total savings were
calculated, and unit prices for 30 count and 90 count prescriptions were compared
between Medicare and the MCCPDC. Of the 15 medications in our sample, Medicare’s
expenditure amounted to $1.8 billion, with the MCCPDC displaying lower prices
overall compared to Medicare. Evaluating 30 count prescriptions, 11 of 15
(73.3%) men’s health drugs resulted in total cost savings of $1.1 billion. For
90 count prescriptions, all 15 drugs yielded savings totaling $1.3 billion. Our
study findings highlight substantial potential for cost savings if Medicare were
to adjust its contracted rates to those currently set by the MCCPDC. We recommend
that healthcare providers include the MCCPDC in patient counseling sessions to
educate patients about accessing medications at lower prices. Integrating the
MCCPDC as a resource can contribute to significant savings and improve medication
affordability. |
| format | Article |
| id | doaj-art-e243626a9027488e8eb4571624871823 |
| institution | Kabale University |
| issn | 1875-6867 1875-6859 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MRE Press |
| record_format | Article |
| series | Journal of Men's Health |
| spelling | doaj-art-e243626a9027488e8eb45716248718232025-01-03T08:41:59ZengMRE PressJournal of Men's Health1875-68671875-68592024-12-012012576410.22514/jomh.2024.200S1875-6867(24)00308-7Reducing men’s health drug costs: exploring the impact of the Mark Cuban Cost Plus Drug Company model on Medicare savingsAdam Khan0Karim Kari1Eli Oldham2Jacob Duncan3Matthew Rashid4Matt Vassar5Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK 74107, USAOffice of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK 74107, USAOffice of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK 74107, USAOffice of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK 74107, USAOffice of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK 74107, USAOffice of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK 74107, USAIn 2022, national health expenditures in the United States were estimated to have grown from 2.7% to 4.3% and increased further in 2023, reaching an estimated $5.2 trillion. Medicare alone, in 2021, accounted for 21% of national health care spending, amounting to $689 billion in total Medicare expenditures. The Mark Cuban Cost Plus Drug Company (MCCPDC) Model offers a solution by providing prescription medications at lower costs. The objective of this study was to assess the effectiveness of the MCCPDC model in reducing men’s health drug costs compared to Medicare Part D. A comprehensive analysis was conducted on the “Men’s Health” drugs available through the MCCPDC. Prices, including dispensing and shipping fees, were collected for the minimum quantity (30 count) and maximum quantity (90 count) from the MCCPDC. Unit costs and total savings were calculated, and unit prices for 30 count and 90 count prescriptions were compared between Medicare and the MCCPDC. Of the 15 medications in our sample, Medicare’s expenditure amounted to $1.8 billion, with the MCCPDC displaying lower prices overall compared to Medicare. Evaluating 30 count prescriptions, 11 of 15 (73.3%) men’s health drugs resulted in total cost savings of $1.1 billion. For 90 count prescriptions, all 15 drugs yielded savings totaling $1.3 billion. Our study findings highlight substantial potential for cost savings if Medicare were to adjust its contracted rates to those currently set by the MCCPDC. We recommend that healthcare providers include the MCCPDC in patient counseling sessions to educate patients about accessing medications at lower prices. Integrating the MCCPDC as a resource can contribute to significant savings and improve medication affordability.https://oss.jomh.org/files/article/20241230-446/pdf/JOMH2024092701.pdfmedicaremen’s health drugsmark cuban cost plus drug companymedication affordabilitycost savings |
| spellingShingle | Adam Khan Karim Kari Eli Oldham Jacob Duncan Matthew Rashid Matt Vassar Reducing men’s health drug costs: exploring the impact of the Mark Cuban Cost Plus Drug Company model on Medicare savings Journal of Men's Health medicare men’s health drugs mark cuban cost plus drug company medication affordability cost savings |
| title | Reducing men’s health drug costs: exploring the impact of the Mark Cuban Cost Plus Drug Company model on Medicare savings |
| title_full | Reducing men’s health drug costs: exploring the impact of the Mark Cuban Cost Plus Drug Company model on Medicare savings |
| title_fullStr | Reducing men’s health drug costs: exploring the impact of the Mark Cuban Cost Plus Drug Company model on Medicare savings |
| title_full_unstemmed | Reducing men’s health drug costs: exploring the impact of the Mark Cuban Cost Plus Drug Company model on Medicare savings |
| title_short | Reducing men’s health drug costs: exploring the impact of the Mark Cuban Cost Plus Drug Company model on Medicare savings |
| title_sort | reducing men s health drug costs exploring the impact of the mark cuban cost plus drug company model on medicare savings |
| topic | medicare men’s health drugs mark cuban cost plus drug company medication affordability cost savings |
| url | https://oss.jomh.org/files/article/20241230-446/pdf/JOMH2024092701.pdf |
| work_keys_str_mv | AT adamkhan reducingmenshealthdrugcostsexploringtheimpactofthemarkcubancostplusdrugcompanymodelonmedicaresavings AT karimkari reducingmenshealthdrugcostsexploringtheimpactofthemarkcubancostplusdrugcompanymodelonmedicaresavings AT elioldham reducingmenshealthdrugcostsexploringtheimpactofthemarkcubancostplusdrugcompanymodelonmedicaresavings AT jacobduncan reducingmenshealthdrugcostsexploringtheimpactofthemarkcubancostplusdrugcompanymodelonmedicaresavings AT matthewrashid reducingmenshealthdrugcostsexploringtheimpactofthemarkcubancostplusdrugcompanymodelonmedicaresavings AT mattvassar reducingmenshealthdrugcostsexploringtheimpactofthemarkcubancostplusdrugcompanymodelonmedicaresavings |